This 2023 expert commentary discusses the 15-year follow-up results of the ProtecT trial, which compared active monitoring, radical prostatectomy, and radiotherapy in men with localized prostate cancer. The trial found no statistically significant difference in prostate cancer-specific mortality among the three treatment modalities, with overall mortality remaining low across the
